本文選題：凍干重組人腦利鈉肽　切入點(diǎn)：左西孟旦　出處：《中國(guó)藥房》2016年08期

【摘要】：目的:觀察凍干重組人腦利鈉肽聯(lián)合左西孟旦治療急性心力衰竭的臨床療效與安全性,考察該聯(lián)合用藥對(duì)患者血清尿酸(UA)與腦鈉肽(BNP)水平的影響。方法:68例急性心力衰竭患者依據(jù)抽簽法隨機(jī)分為觀察組與對(duì)照組,各34例。兩組患者均給予常規(guī)治療,在此基礎(chǔ)上對(duì)照組患者給予左西孟旦注射液5 ml加入0.9%氯化鈉注射液45 ml中持續(xù)微泵注射:開始后第1 h內(nèi)泵注速率為12μg/(kg·min),之后以0.5μg/(kg·min)的速率持續(xù)給藥23 h;觀察組患者在對(duì)照組基礎(chǔ)上給予凍干重組人腦利鈉肽1.5μg/kg靜脈沖擊,之后以7.5 ng/(kg·min)的速率持續(xù)靜脈滴注3~7 d。觀察兩組患者的臨床療效,治療前后血清UA、BNP與心功能指標(biāo)的變化,以及用藥安全性。結(jié)果:治療后,觀察組患者的總有效率(94.11%)顯著高于對(duì)照組(70.59%),差異有統(tǒng)計(jì)學(xué)意義(P0.05);觀察組患者的血清UA與BNP水平改善程度明顯優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05);觀察組患者的每搏輸出量與左心室射血分?jǐn)?shù)明顯優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。觀察組患者的不良反應(yīng)發(fā)生率(2.94%)與對(duì)照組(5.88%)比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:凍干重組人腦利鈉肽聯(lián)合左西孟旦治療急性心力衰竭臨床療效明顯、安全性高。
[Abstract]:Aim: to observe the clinical efficacy and safety of freeze-dried recombinant human brain natriuretic peptide combined with levosimendan in the treatment of acute heart failure, and to investigate the effects of the combined therapy on the levels of serum uric acid and brain natriuretic peptide (BNPs) in patients with acute heart failure.Methods 68 patients with acute heart failure were randomly divided into observation group and control group.Both groups were given routine treatment.On this basis, the patients in the control group were treated with 5 ml of levosimendan injection and 45 ml of 0.9% sodium chloride injection: the injection rate was 12 渭 g/(kg / min within 1 h after the beginning of injection, and then the drug was administered at the rate of 0.5 渭 g/(kg / min for 23 h in the observation group.Patients were given intravenous shock of 1. 5 渭 g/kg of recombinant human brain natriuretic peptide on the basis of control group.After that, continuous intravenous drip was given at the rate of 7.5 ng/(kg for 7 d.To observe the clinical effect of the two groups, the changes of serum UABNP and cardiac function indexes before and after treatment, and the safety of medication.Results: after treatment, the total effective rate of patients in the observation group was significantly higher than that in the control group (70.59), the difference was statistically significant (P 0.05), the improvement of serum UA and BNP levels in the observation group was significantly better than that in the control group.The difference was statistically significant (P 0.05), and the stroke output and left ventricular ejection fraction (LVEF) in the observation group were significantly better than those in the control group (P 0.05).There was no significant difference in the incidence of adverse reactions between the observation group (2.94) and the control group (5.88).Conclusion: freeze-dried recombinant human brain natriuretic peptide combined with levosimendan is effective and safe in the treatment of acute heart failure.
【作者單位】： 解放軍第117醫(yī)院心內(nèi)科;
【分類號(hào)】：R541.6
，

本文編號(hào)：1713511